Advertisement

Topics

Q&A: Bayer Comments on Recent FDA Approval of Stivarga

08:00 EDT 30 Jun 2017 | PharmPro

Mark Rutstein, Vice President of Oncology Clinical Development at Bayer, provides insight on the company’s latest FDA approval.
Staff Author: 

Original Article: Q&A: Bayer Comments on Recent FDA Approval of Stivarga

NEXT ARTICLE

More From BioPortfolio on "Q&A: Bayer Comments on Recent FDA Approval of Stivarga"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...